Compare Stocks: ZTS, BMY, SNY, and GSK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.60 +0.0%	$63.99	$42.52 ▼ $68.64	$117.66B	0.19	12.00 million shs	46,464 shs
GSK GSK	$47.03 +0.2%	$49.92	$42.85 ▼ $61.69	$95.12B	0.33	4.44 million shs	25,690 shs
SNY Sanofi	$40.00 +0.7%	$42.93	$39.18 ▼ $52.68	$97.22B	0.33	3.10 million shs	2.94 million shs
ZTS Zoetis	$75.74 +0.1%	$73.89	$68.77 ▼ $148.30	$31.30B	0.74	5.53 million shs	11,329 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-2.61%	-1.87%	-9.27%	+1.14%	+30.97%
GSK GSK	+0.68%	+0.58%	-2.75%	-8.70%	+7.55%
SNY Sanofi	-0.82%	+0.58%	-7.08%	-7.97%	-17.36%
ZTS Zoetis	+1.04%	+5.80%	+3.42%	+1.98%	-46.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.60 +0.0%	$63.99	$42.52 ▼ $68.64	$117.66B	0.19	12.00 million shs	46,464 shs
GSK GSK	$47.03 +0.2%	$49.92	$42.85 ▼ $61.69	$95.12B	0.33	4.44 million shs	25,690 shs
SNY Sanofi	$40.00 +0.7%	$42.93	$39.18 ▼ $52.68	$97.22B	0.33	3.10 million shs	2.94 million shs
ZTS Zoetis	$75.74 +0.1%	$73.89	$68.77 ▼ $148.30	$31.30B	0.74	5.53 million shs	11,329 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-2.61%	-1.87%	-9.27%	+1.14%	+30.97%
GSK GSK	+0.68%	+0.58%	-2.75%	-8.70%	+7.55%
SNY Sanofi	-0.82%	+0.58%	-7.08%	-7.97%	-17.36%
ZTS Zoetis	+1.04%	+5.80%	+3.42%	+1.98%	-46.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.47	Hold	$65.08	12.98% Upside
GSK GSK	2.05	Hold	$55.33	17.66% Upside
SNY Sanofi	2.38	Hold	$49.50	23.75% Upside
ZTS Zoetis	2.32	Hold	$101.08	33.45% Upside

Current Analyst Ratings Breakdown

Latest ZTS, BMY, SNY, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$76.00
10/12/2026	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
10/9/2026	BMY Bristol Myers Squibb	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$71.00 ➝ $66.00
10/9/2026	GSK GSK	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$70.00
10/9/2026	SNY Sanofi	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Peer Perform
10/8/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
10/8/2026	BMY Bristol Myers Squibb	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$51.00 ➝ $53.00
10/8/2026	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$59.00 ➝ $53.00
10/7/2026	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight	$40.00 ➝ $41.00
10/6/2026	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	BMY Bristol Myers Squibb	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$73.00 ➝ $59.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$49.19B	2.39	$7.92 per share	7.27	$9.09 per share	6.34
GSK GSK	$43.07B	2.21	$6.08 per share	7.74	$10.32 per share	4.56
SNY Sanofi	$49.35B	1.97	$7.05 per share	5.67	$33.27 per share	1.20
ZTS Zoetis	$9.47B	3.31	$7.66 per share	9.89	$7.56 per share	10.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$4.54	12.69	8.78	0.29	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
GSK GSK	$7.54B	$3.20	14.71	9.41	2.09	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	20.99	7.63	1.23	8.66%	14.19%	7.95%	10/30/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	12.48	11.97	1.75	27.49%	74.89%	18.59%	11/5/2026 (Estimated)

Latest ZTS, BMY, SNY, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZTS Zoetis	$1.52	N/A	N/A	N/A	$2.30 billion	N/A
10/30/2026	Q3 2026	SNY Sanofi	$1.70	N/A	N/A	N/A	$15.37 billion	N/A
10/29/2026	Q3 2026	BMY Bristol Myers Squibb	$1.70	N/A	N/A	N/A	$12.71 billion	N/A
10/28/2026	Q3 2026	GSK GSK	$1.34	N/A	N/A	N/A	$11.82 billion	N/A
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.37%	+1.61%	55.51%	17 Years
GSK GSK	$1.77	3.78%	-7.86%	55.31%	N/A
SNY Sanofi	$1.76	4.43%	+6.46%	92.15%	N/A
ZTS Zoetis	$2.12	2.81%	+20.11%	34.93%	14 Years

Latest ZTS, BMY, SNY, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/8/2026	ZTS Zoetis	quarterly	$0.53	2.9%	10/30/2026	10/30/2026	12/1/2026
9/15/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.12%	10/2/2026	10/2/2026	11/2/2026
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	1.89	1.53	1.38
GSK GSK	0.81	0.82	0.52
SNY Sanofi	0.21	0.99	0.64
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GSK GSK	15.74%
SNY Sanofi	14.03%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
GSK GSK	10.00%
SNY Sanofi	1.00%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

ZTS, BMY, SNY, and GSK Headlines

Recent News About These Companies

Zoetis Appoints Iris Knobloch to Board of Directors

1 hour ago | tipranks.com

Zoetis Appoints Iris Knobloch to its Board of Directors

1 hour ago | businesswire.com

Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure Persists

October 11 at 3:16 PM | finance.yahoo.com

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

October 9, 2026 | zacks.com

Zoetis Inc. (NYSE:ZTS) Plans Quarterly Dividend of $0.53

October 9, 2026 | marketbeat.com

Zoetis (ZTS) Declares $0.53 Quarterly Dividend; 2.9% Yield

October 8, 2026 | streetinsider.com

Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm

October 8, 2026 | finance.yahoo.com

Zoetis Declares Fourth-Quarter Dividend, Signals Ongoing Strength

October 8, 2026 | tipranks.com

Zoetis Declares Fourth Quarter 2026 Dividend

October 8, 2026 | businesswire.com

Zoetis hits a new 52-week low as Zoetis stock gains 2.86 percent

October 6, 2026 | ad-hoc-news.deA

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

October 6, 2026 | businesswire.com

MarketBeat cites Hold consensus for Zoetis stock

October 5, 2026 | ad-hoc-news.deA

40,294 Zoetis Inc. $ZTS Shares Purchased by Rockland Trust Co.

October 5, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Eli Lilly & Co (LLY) and Liquidia Technologies (LQDA)

October 2, 2026 | theglobeandmail.com

Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?

October 1, 2026 | insidermonkey.com

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

October 1, 2026 | zacks.com

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

October 1, 2026 | finance.yahoo.com

Zoetis Inc. (NYSE:ZTS) Stock Rated "Hold" by Wall Street Analysts

October 1, 2026 | marketbeat.com

Zoetis (NYSE:ZTS) Hits New 1-Year Low - What's Next?

September 30, 2026 | marketbeat.com

Zoetis: Priced For The Worst, Worth Buying

September 30, 2026 | seekingalpha.com

483,862 Zoetis Inc. $ZTS Shares Sold by Envestnet Asset Management Inc.

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

$57.60 +0.02 (+0.04%)

As of 09:31 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$47.03 +0.11 (+0.23%)

As of 09:31 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi NASDAQ:SNY

$40.00 +0.26 (+0.65%)

As of 09:31 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Zoetis NYSE:ZTS

$75.74 +0.09 (+0.12%)

As of 09:31 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, BMY, SNY, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, BMY, SNY, and GSK Earnings

Compare Dividends

Latest ZTS, BMY, SNY, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, BMY, SNY, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

GSK NYSE:GSK

Sanofi NASDAQ:SNY

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, BMY, SNY, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, BMY, SNY, and GSK Earnings

Compare Dividends

Latest ZTS, BMY, SNY, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, BMY, SNY, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

GSK NYSE:GSK

Sanofi NASDAQ:SNY

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools